Novartis AG (NYSE:NVS) Stake Reduced by Aspiriant LLC
Aspiriant LLC reduced its stake in shares of Novartis AG (NYSE:NVS) by 7.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,226 shares of the company’s stock after selling 407 shares during the quarter. Aspiriant LLC’s holdings in Novartis were worth $454,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Asset Dedication LLC boosted its position in Novartis by 98.7% during the 2nd quarter. Asset Dedication LLC now owns 304 shares of the company’s stock worth $27,000 after acquiring an additional 151 shares during the period. Moneta Group Investment Advisors LLC boosted its position in Novartis by 795.8% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 2,750 shares of the company’s stock worth $27,000 after acquiring an additional 2,443 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA boosted its position in Novartis by 330.4% during the 3rd quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 340 shares of the company’s stock worth $30,000 after acquiring an additional 261 shares during the period. Vigilant Capital Management LLC acquired a new position in Novartis during the 2nd quarter worth $37,000. Finally, Anderson Fisher LLC acquired a new position in Novartis during the 2nd quarter worth $39,000. Hedge funds and other institutional investors own 11.19% of the company’s stock.
Shares of Novartis stock opened at $88.37 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 0.42. The firm has a market cap of $199.13 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.94 and a beta of 0.59. The business has a fifty day simple moving average of $86.81 and a 200-day simple moving average of $87.75. Novartis AG has a fifty-two week low of $72.19 and a fifty-two week high of $95.00.
A number of research analysts have issued reports on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Novartis in a research report on Thursday, August 29th. ValuEngine upgraded Novartis from a “sell” rating to a “hold” rating in a research report on Saturday, October 19th. Kepler Capital Markets lowered Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Cowen reiterated a “buy” rating and set a $100.00 price target on shares of Novartis in a research report on Friday, October 25th. Finally, Argus boosted their price target on Novartis to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. They noted that the move was a valuation call. Four analysts have rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Novartis has an average rating of “Hold” and a consensus price target of $95.28.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Featured Story: Why do analysts give a neutral rating?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.